Piper Sandler upgraded shares of Humacyte (NASDAQ:HUMA – Free Report) from an underweight rating to a neutral rating in a research note issued to investors on Monday, Marketbeat reports. The brokerage currently has $3.50 price objective on the stock, up from their previous price objective of $2.75. Separately, Cantor Fitzgerald initiated coverage on Humacyte in […] The post Humacyte (NASDAQ:HUMA) Raised to Neutral at Piper Sandler first appeared on Daily Political .

https://www.dailypolitical.com/2023/08/18/humacyte-nasdaqhuma-raised-to-neutral-at-piper-sandler.html

#dailypolitical